Pill Identifier App

Lucentis Sales Data

Rank 26 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Lucentis U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 26 -0.84% 0.36%
Q3 2013 26 (1) 2.52% 2.62%
Q2 2013 27 (2) 9.07% 10.33%
Q1 2013 29 (1) 4.92% 6.14%
Q4 2012 30 (1) 3.63% 7.04%
Q3 2012 31 (6) -1.88%
Q2 2012 37 (2) -4.92% -4.91%
Q1 2012 35 (5) -6.89% -5.88%
Q4 2011 30 (2) 2.44% 2.59%
Q3 2011 28 (2) 1.13% 0.87%
Q2 2011 30 (3) 0.95% 1.32%
Q1 2011 33

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
August 10, 2012FDA Gives Nod to Lucentis for Diabetic Eye Disease
August 10, 2012Lucentis Approved for Diabetic Macular Edema
September 12, 2011Eye Antibiotics Can Cause Drug-Resistant Bacteria: Study
January 7, 2011Novartis International AG (CH) - Novartis Gains New Indication for Lucentis in EU for Vision Loss due to Diabetic Macular Edema, a Leading Cause of Blindness
Hide
(web4)